We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phytopharm | LSE:PYM | London | Ordinary Share | GB00BCLY7L40 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
TIDMIXI
RNS Number : 2054G
IXICO plc
18 November 2015
18 November 2015
IXICO plc
("IXICO" or the "Company")
Publication of Circular and Notice of General Meeting
18 November 2015: IXICO plc (AIM: IXI), the brain health company, today confirms that further to the announcement made earlier today, a Circular has been published and will be posted to shareholders today in relation to the Proposed Acquisition, Placing, Broker Option, Rule 9 Waiver and Share Restructuring (all of which remain subject to approval by shareholders at a General Meeting to be held on 7 December 2015).
A copy of the Circular will shortly be available on the Company's website at the following URL: http://www.ixico.com/investors/companydocuments.
For further information, please contact:
IXICO plc Tel: +44 (0) 20 3763 7499 Derek Hill, CEO Susan Lowther, CFO Charles Spicer, VP Corporate Development Peel Hunt LLP (Nominated Adviser Tel: +44 (0) 20 7418 8900 and Broker) James Steel Oliver Jackson Sohail Akbar FTI Consulting Limited (Investor Tel: +44 (0) 20 3727 1000 Relations) Simon Conway Mo Noonan Matthew Moss
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CIRPKFDNPBDDNDD
(END) Dow Jones Newswires
November 18, 2015 10:45 ET (15:45 GMT)
1 Year Phytopharm Chart |
1 Month Phytopharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
